FDA Approves Merck's Vaxneuvance For Prevention Of Invasive Pneumococcal Disease In Children

KENILWORTH (NJ) (dpa-AFX) - The U.S. Food and Drug Administration has approved an expanded indication for Vaxneuvance (Pneumococcal 15-valent Conjugate Vaccine) to include children 6 weeks through

Related Keywords

,Merck Co Inc ,Us Centers For Disease ,Drug Administration ,Prevention Advisory Committee On Immunization Practices ,Conjugate Vaccine ,Disease Control ,Advisory Committee ,Immunization Practices ,Approves ,Merck ,Vaxneuvance ,Prevention ,Nvasive ,Pneumococcal ,Disease ,Children ,